Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
2 Acute myeloid leukemia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
3 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
4 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
5 Adrenergic signaling in cardiomyocytes 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
6 Adrenergic signaling in cardiomyocytes 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
7 Adrenergic signaling in cardiomyocytes 💬
 1件: SCN5A 💬 D00358 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
8 Adrenergic signaling in cardiomyocytes 💬
 1件: SCN5A 💬 D02086 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
9 Adrenergic signaling in cardiomyocytes 💬
 1件: SCN5A 💬 D08127 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
11 Alanine, aspartate and glutamate metabolism 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
12 Aldosterone synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
13 Alzheimer disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
14 Alzheimer disease 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
15 Alzheimer disease 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
16 Amoebiasis 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
17 AMPK signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
18 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
19 Amyotrophic lateral sclerosis 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
20 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
21 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
22 Apelin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
23 Arachidonic acid metabolism 💬
 2件: PTGS1, PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
24 Autophagy - animal 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
25 Autophagy - other 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
26 beta-Alanine metabolism 💬
 3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
27 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
28 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
29 Breast cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
30 Butanoate metabolism 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
31 C-type lectin receptor signaling pathway 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
32 Calcium signaling pathway 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
33 Calcium signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
34 Calcium signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
35 Calcium signaling pathway 💬
 1件: HRH1 💬 D00300 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
36 Calcium signaling pathway 💬
 1件: HRH1 💬 D00669 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
37 Calcium signaling pathway 💬
 1件: HRH1 💬 D02419 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
38 Calcium signaling pathway 💬
 1件: HRH1 💬 D03285 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
39 Calcium signaling pathway 💬
 1件: HRH1 💬 D03360 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
40 Calcium signaling pathway 💬
 1件: HRH1 💬 D03854 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
41 cAMP signaling pathway 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
42 cAMP signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
43 Cellular senescence 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
44 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
45 cGMP-PKG signaling pathway 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
46 cGMP-PKG signaling pathway 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
47 Chemical carcinogenesis - DNA adducts 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
48 Chemical carcinogenesis - receptor activation 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
49 Chemical carcinogenesis - receptor activation 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
50 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
51 Chemical carcinogenesis - receptor activation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
52 Chemokine signaling pathway 💬
 2件: JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
53 Choline metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
54 Cholinergic synapse 💬
 1件: ACHE 💬 D00487 💬 Pyridostigmine 4件:  3 ,  6 , 11, 256 💬
55 Cholinergic synapse 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
56 Circadian entrainment 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
57 Colorectal cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
58 Coronavirus disease - COVID-19 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
59 Coronavirus disease - COVID-19 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
60 Cortisol synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
61 Cushing syndrome 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
62 Cytokine-cytokine receptor interaction 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
63 Cytokine-cytokine receptor interaction 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
64 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
65 Dopaminergic synapse 💬
 1件: SCN1A 💬 D00358 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
66 Dopaminergic synapse 💬
 1件: SCN1A 💬 D02086 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
67 Dopaminergic synapse 💬
 1件: SCN1A 💬 D08127 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
68 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
69 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
70 Endocrine resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
71 Epstein-Barr virus infection 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
72 ErbB signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
73 Fc epsilon RI signaling pathway 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
74 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
75 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
76 GABAergic synapse 💬
 3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
77 Galactose metabolism 💬
 1件: GAA 💬 D03207 💬 Alglucosidase alfa 1件: 256 💬
78 Galactose metabolism 💬
 1件: GAA 💬 D11744 💬 Avalglucosidase alfa 1件: 256 💬
79 Galactose metabolism 💬
 1件: GAA 💬 D11798 💬 Cipaglucosidase alfa 1件: 256 💬
80 Galactose metabolism 💬
 1件: GAA 💬 D09605 💬 Duvoglustat 1件: 256 💬
81 Gastric cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
82 Glioma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
83 Glycerophospholipid metabolism 💬
 1件: ACHE 💬 D00487 💬 Pyridostigmine 4件:  3 ,  6 , 11, 256 💬
84 Glycosaminoglycan degradation 💬
 1件: IDUA 💬 D04670 💬 Laronidase 2件: 19, 256 💬
85 GnRH secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
86 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
87 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
88 Hematopoietic cell lineage 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
89 Hematopoietic cell lineage 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
90 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 D02994 💬 Rituximab 49件:  6 , 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
91 Hepatitis B 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
92 Hepatitis C 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
93 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
94 Herpes simplex virus 1 infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
95 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
96 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
97 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
98 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
99 Human cytomegalovirus infection 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
100 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
101 Human papillomavirus infection 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
102 Human papillomavirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
103 Human papillomavirus infection 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
104 Human T-cell leukemia virus 1 infection 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
105 Human T-cell leukemia virus 1 infection 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
106 Huntington disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
107 Huntington disease 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
108 IL-17 signaling pathway 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
109 IL-17 signaling pathway 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
110 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 D00300 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
111 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 D00669 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
112 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 D02419 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
113 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 D03285 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
114 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 D03360 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
115 Inflammatory mediator regulation of TRP channels 💬
 1件: HRH1 💬 D03854 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
116 Influenza A 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
117 Insulin resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
118 Insulin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
119 JAK-STAT signaling pathway 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
120 JAK-STAT signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
121 JAK-STAT signaling pathway 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
122 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
123 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
124 Kaposi sarcoma-associated herpesvirus infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
125 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
126 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
127 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
128 Leishmaniasis 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
129 Lipid and atherosclerosis 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
130 Longevity regulating pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
131 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
132 Lysosome 💬
 1件: GAA 💬 D03207 💬 Alglucosidase alfa 1件: 256 💬
133 Lysosome 💬
 1件: GAA 💬 D11744 💬 Avalglucosidase alfa 1件: 256 💬
134 Lysosome 💬
 1件: GAA 💬 D11798 💬 Cipaglucosidase alfa 1件: 256 💬
135 Lysosome 💬
 1件: GAA 💬 D09605 💬 Duvoglustat 1件: 256 💬
136 Lysosome 💬
 1件: IDUA 💬 D04670 💬 Laronidase 2件: 19, 256 💬
137 MAPK signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
138 Measles 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
139 Metabolic pathways 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
140 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
141 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
142 Metabolic pathways 💬
 1件: GAA 💬 D03207 💬 Alglucosidase alfa 1件: 256 💬
143 Metabolic pathways 💬
 1件: GAA 💬 D11744 💬 Avalglucosidase alfa 1件: 256 💬
144 Metabolic pathways 💬
 1件: GAA 💬 D11798 💬 Cipaglucosidase alfa 1件: 256 💬
145 Metabolic pathways 💬
 1件: GAA 💬 D09605 💬 Duvoglustat 1件: 256 💬
146 Metabolic pathways 💬
 1件: IDUA 💬 D04670 💬 Laronidase 2件: 19, 256 💬
147 Metabolic pathways 💬
 2件: PTGS1, PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
148 Metabolic pathways 💬
 1件: UGCG 💬 D05032 💬 Miglustat 3件: 19, 256, 299 💬
149 MicroRNAs in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
150 MicroRNAs in cancer 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
151 mTOR signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
152 Natural killer cell mediated cytotoxicity 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
153 Necroptosis 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
154 Neuroactive ligand-receptor interaction 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
155 Neuroactive ligand-receptor interaction 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
156 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 D00300 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
157 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 D00669 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
158 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 D02419 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
159 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 D03285 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
160 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 D03360 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
161 Neuroactive ligand-receptor interaction 💬
 1件: HRH1 💬 D03854 💬 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 💬
162 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
163 NF-kappa B signaling pathway 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
164 NOD-like receptor signaling pathway 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
165 Non-small cell lung cancer 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
166 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
167 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
168 Osteoclast differentiation 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
169 Ovarian steroidogenesis 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
170 Oxytocin signaling pathway 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
171 Pancreatic cancer 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
172 Pancreatic cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
173 Parkinson disease 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
174 Pathways in cancer 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
175 Pathways in cancer 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
176 Pathways in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
177 Pathways in cancer 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
178 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
179 Pathways of neurodegeneration - multiple diseases 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
180 Pathways of neurodegeneration - multiple diseases 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
181 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
182 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
183 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
184 PI3K-Akt signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 34件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
185 PI3K-Akt signaling pathway 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
186 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
187 Platelet activation 💬
 1件: PTGS1 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
188 Primary immunodeficiency 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
189 Prion disease 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
190 Prolactin signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
191 Propanoate metabolism 💬
 1件: ABAT 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
192 Prostate cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
193 Proteasome 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
194 Proteoglycans in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
195 Regulation of lipolysis in adipocytes 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
196 Regulation of lipolysis in adipocytes 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
197 Regulation of lipolysis in adipocytes 💬
 2件: PTGS1, PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
198 Renin secretion 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
199 Renin secretion 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
200 Retrograde endocannabinoid signaling 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
201 Rheumatoid arthritis 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
202 Salivary secretion 💬
 1件: ADRB2 💬 D07713 💬 Clenbuterol 5件:  1 ,  2 ,  6 , 13, 256 💬
203 Salivary secretion 💬
 1件: ADRB2 💬 D02147 💬 Salbutamol 14件:  3 , 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
204 Serotonergic synapse 💬
 2件: PTGS1, PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
205 Shigellosis 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
206 Shigellosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
207 Signaling pathways regulating pluripotency of stem cells 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
208 Small cell lung cancer 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
209 Sphingolipid metabolism 💬
 1件: UGCG 💬 D05032 💬 Miglustat 3件: 19, 256, 299 💬
210 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
211 Spinocerebellar ataxia 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 💬
212 Starch and sucrose metabolism 💬
 1件: GAA 💬 D03207 💬 Alglucosidase alfa 1件: 256 💬
213 Starch and sucrose metabolism 💬
 1件: GAA 💬 D11744 💬 Avalglucosidase alfa 1件: 256 💬
214 Starch and sucrose metabolism 💬
 1件: GAA 💬 D11798 💬 Cipaglucosidase alfa 1件: 256 💬
215 Starch and sucrose metabolism 💬
 1件: GAA 💬 D09605 💬 Duvoglustat 1件: 256 💬
216 T cell receptor signaling pathway 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
217 Taste transduction 💬
 3件: SCN2A, SCN3A, SCN9A 💬 D00358 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
218 Taste transduction 💬
 3件: SCN2A, SCN3A, SCN9A 💬 D02086 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
219 Taste transduction 💬
 3件: SCN2A, SCN3A, SCN9A 💬 D08127 💬 Lidocaine 13件:  6 , 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256 💬
220 Taurine and hypotaurine metabolism 💬
 2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
221 Th1 and Th2 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
222 Th17 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
223 Th17 cell differentiation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
224 Thermogenesis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
225 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
226 TNF signaling pathway 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
227 TNF signaling pathway 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
228 Toxoplasmosis 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
229 Transcriptional misregulation in cancer 💬
 1件: CSF2 💬 D11343 💬 Otilimab 2件: 46, 256 💬
230 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬
231 Type I diabetes mellitus 💬
 2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
232 Type II diabetes mellitus 💬
 1件: CACNA1G 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
233 Type II diabetes mellitus 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 41件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
234 Valine, leucine and isoleucine degradation 💬
 1件: ABAT 💬 D00399 💬 Valproic acid 17件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331 💬
235 VEGF signaling pathway 💬
 1件: PTGS2 💬 D00217 💬 Acetaminophen 18件:  3 ,  6 , 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 💬
236 Viral carcinogenesis 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 💬

先頭へ